Skip to main content
OpenTrials

Clinical trial condition

Diffuse Large B-cell Lymphoma

Explore clinical trials studying Diffuse Large B-cell Lymphoma. Study availability and eligibility vary by location and protocol.

213 public trials 54 recruiting studies
Refine in advanced search Browse all conditions

Diffuse Large B-cell Lymphoma trial results

Recruiting

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017

Conditions
DLBCL, Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, +10 more
Locations
  • Palo Verde Hematology/ Oncology Center, Ltd. ( Site 0175) Glendale, Arizona, United States
  • Beverly Hills Cancer Center ( Site 0184) Beverly Hills, California, United States
  • Bass Medical Group ( Site 0166) Walnut Creek, California, United States
  • Innovative Clinical Research Institute ( Site 0122) Whittier, California, United States
View all 135 locations
View Trial Details
Recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

NCT06717347

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • USA Mitchell Cancer Institute ( Site 0173) Mobile, Alabama, United States
  • Banner MD Anderson Cancer Center ( Site 0165) Gilbert, Arizona, United States
  • Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0167) Phoenix, Arizona, United States
  • The University of Arizona Cancer Center - North Campus ( Site 0124) Tucson, Arizona, United States
View all 268 locations
View Trial Details
Recruiting

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

NCT06395103

Conditions
B-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, DNA Virus Infections, +32 more
Locations
  • Children's Hospital Los Angeles ( Site 1006) Los Angeles, California, United States
  • Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016) Aurora, Colorado, United States
  • Yale New Haven Hospital ( Site 1012) New Haven, Connecticut, United States
  • Johns Hopkins All Children's Hospital ( Site 1025) St. Petersburg, Florida, United States
View all 71 locations
View Trial Details
Recruiting

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686

Conditions
Blood Protein Disorders, Bronchial Diseases, Bronchiolitis, +43 more
Locations
  • City of Hope Cancer Center Duarte, California, United States
  • University of California San Diego Medical Center La Jolla, California, United States
  • University of California Los Angeles Los Angeles, California, United States
  • St. Joseph Hospital Center for Cancer Prevention and Treatment Orange, California, United States
View all 175 locations
View Trial Details
Recruiting

An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma

NCT07200375

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Cancer Hospital Chinese Academy of Medical Sciences. Langfang, Hebei, China
  • Chinese Academy of Medical Sciences Hematology Hospital;Lymphoma Diagnosis and Treatment Center Tianjin, Tianjin Municipality, China
  • Peking University People's Hospital Beijing, China
  • Peking University Third Hospital Beijing, China
View all 19 locations
View Trial Details

Related conditions